Boyds is pleased to announce the appointment of Moira Francois as Senior Manager, CMC Regulatory Affairs.
With more than ten years’ experience in ATMP analytical development, manufacturing, and regulatory affairs, Moira joins Boyds from the Cell and Gene Therapy Catapult where she was a Regulatory Manager focusing on CMC projects across both cell and gene therapies. Before this, she was part of the analytical development team at the Catapult, working on the development of analytical assays for pluripotent stem cell-based drug products.
Previously, Moira was a secondee for the MHRA British Pharmacopoeia’s ATMP Working Party, contributing to the development of best practice documents in relation to advanced therapies.
Moira completed her PhD in Experimental Medicine at McGill University in Montreal, Canada, where her research focused on the use of mesenchymal stromal cells for immunomodulation. She then moved to the UK to complete a postdoctoral fellowship at Imperial College London, investigating the biological functions of mesenchymal stromal cell subpopulations.
At Boyds, she will specialise in CMC regulatory affairs, working closely with Claire Scruton, Senior Director of Regulatory Affairs, to support the delivery of CMC aspects of client projects.
Commenting on joining Boyds, Moira said: “I was drawn to Boyds because of its unparalleled drug development expertise and collaborative culture. In my new role, I’m excited to contribute my experience in ATMP development whilst continuing to develop and learn from the team.”